New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
CellTalk Blog
CAR Kinetics in Autoimmune Studies: Expert Insights on Designing Effective Monitoring Strategies
June 30, 2026
More infoCellTalk Blog
Cytokine Profiling in Autoimmune Programs: Expert Insights on Assay Selection and Getting Data You Can Trust
June 30, 2026
More infoCellTalk Blog
Designing T-Cell Activation and Exhaustion Assays for Autoimmune Programs: Expert Insights
June 30, 2026
More info